• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

    2.325 -0.015 (-0.64%)
    Streaming Delayed Price Updated: 3:55 PM EDT, Jun 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Acumen Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    News headline image
    Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals's Earnings Outlook ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals's Earnings: A Preview ↗
     
    Via Benzinga
    News headline image
    Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot ↗
    Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
    Via InvestorPlace
    News headline image
    3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom ↗
    These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
    Via InvestorPlace
    News headline image
    Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
    ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
    Via Talk Markets
    Topics ETFs
    News headline image
    Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
    Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
    Via Investor's Business Daily
    News headline image
    Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 13, 2023 ↗
    Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
    Via Benzinga
    News headline image
    Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
    Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
    Via InvestorPlace
    News headline image
    3 Promising Biotech Stocks Flying Under the Radar ↗
    Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
    Via InvestorPlace
    News headline image
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
    Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗
    Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
    --News Direct-- 
    Via News Direct
    News headline image
    $40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗
    Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
    Via Benzinga
    News headline image
    MarketBeat Week in Review – 7/17 - 7/21
    Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks 
    Via MarketBeat
    Topics Economy
    News headline image
    Acumen Soars on Alzheimer's Study...Street Sees It Doubling
    Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price? 
    Via MarketBeat
    Topics Initial Public Offering
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.